Looking for some insights into the way that environment and biology influence the development of multiple sclerosis, Biogen Idec ($BIIB) will team up with online overlord Google ($GOOG) to sift through a mountain of data on the topic, according to a report from Bloomberg. The big goal for Biogen, a leader in the field, is to get a better idea of why some patients see the disease progress so much faster than others. And if it's successful, they could get information that will help guide prescribing existing drugs as well as develop new ones. This is Google X labs' second big pharma collaboration. Story